Recent Updates — NIVF
NewGenIvf Group Limited reported a net loss attributable to shareholders of $8.04 million for the six months ended June 30, 2026, compared to a net profit of $725,000 in the same period last year. The loss was driven by a $3.42 million one-off expense from a repurchase and forbearance agreement with JAK Opportunities VI LLC and increased interest expenses totaling $541,133. Revenue slightly declined to $1.92 million from $2.02 million, but gross profit margin improved significantly to 24.1% from 15.5%, primarily due to a business model shift in Kyrgyzstan from IVF clinic operations to fertility referral services. The company also raised $2.13 million through the issuance of convertible notes during the period and completed strategic investments, including acquiring up to 10% equity interest in PredicXion Group Limited at a pre-money valuation of $100 million. NewGenIvf operates in the fertility treatment industry, providing IVF services and referral networks across multiple countries.
The board approved a one-for-four reverse stock split to be effective on October 12, 2026. The action reduces outstanding Class A ordinary shares from approximately 35.7 million to roughly 8.9 million and adjusts convertible securities proportionally without requiring shareholder approval. NewGenIvf Group Limited operates in the fertility and reproductive health sector.
NewGenIvf Group Limited closed a public offering on September 30, 2026, raising approximately $1.25 million in gross proceeds. The company issued an aggregate of 17,857,143 Class A ordinary shares and pre-funded warrants at a price of $0.07 per share. Aegis Capital Corp. acted as the exclusive placement agent for the best-efforts offering. Net proceeds will fund investments in K25.ai, debt restructuring, working capital for Nodexus machine deployment, and general corporate purposes. Concurrently, officers, directors, and employees entered into 60-day lock-up agreements restricting the sale of their shares. NewGenIvf Group Limited operates in the technology sector with diversified interests in real estate development, digital asset management, and reproductive health solutions.
On July 31, 2026, the Board of Directors approved a reverse stock split at a ratio of one-for-three. The transaction becomes effective on September 1, 2026, with split-adjusted trading commencing that day under symbol NIVF and new CUSIP G0544E154. Outstanding Class A Ordinary Shares will decrease from approximately 6,307,870 to roughly 2,102,623. Fractional shares are consolidated into whole shares rather than cashed out. Convertible securities are adjusted by dividing share counts by three. NewGenIvf Group Limited operates in the fertility and reproductive health services industry.